ReviewJournal of neurology2021
Axonal degeneration in Guillain-Barré syndrome: a reappraisal.
Review in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Sinomenine ameliorates experimental autoimmune neuritis by suppressing pro-inflammatory immune components and restoring immune balance.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Screening of signaling pathways and hub genes in Guillain-Barré syndrome based on bioinformatics and machine learning.BMC neurology · 2026Article
- MR neurography of tibial and common peroneal nerves in patients with Guillain-Barre syndrome and electrophysiological correlation.BMC neurology · 2026Article
- The role of L-DOPA in neurological and neurodegenerative complications: a review.Molecular and cellular biochemistry · 2025Review
- Blood nerve barrier permeability enables nerve targeting of circulating nanoparticles in experimental autoimmune neuritis.Scientific reports · 2025Article
- How Do Peripheral Neurons and Glial Cells Participate in Pain Alleviation by Physical Activity?Cells · 2025Review
- Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity.Journal of veterinary science · 2024Article
- Small fibre integrity and axonal pathology in the rat model of experimental autoimmune neuritis.Brain communications · 2024Article
- Kinesin-5 inhibition improves neural regeneration in experimental autoimmune neuritis.Journal of neuroinflammation · 2023Article
- The endogenous calpain inhibitor calpastatin attenuates axon degeneration in murine Guillain-Barré syndrome.Journal of the peripheral nervous system : JPNS · 2023Article
- Very low peroneal nerve compound muscle action potential amplitude predicts poor outcome in patients with Guillain-Barré syndrome: a prospective cohort.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Observational
- Pathogenic events in very early Guillain-Barré syndrome: neither demyelination nor axonal degeneration but endoneurial inflammatory oedema.Journal of neurology · 2022Article
- Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis.Frontiers in immunology · 2022Review
- Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Neuropsychiatric Manifestations of COVID-19: A Review.Advances in psychiatry and behavioral health · 2021Review
- Bioinformatic analyses hinted at augmented T helper 17 cell differentiation and cytokine response as the central mechanism of COVID-19-associated Guillain-Barré syndrome.Cell proliferation · 2021Article
- New evidence for secondary axonal degeneration in demyelinating neuropathies.Neuroscience letters · 2021Review
- Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated Guillain-Barré syndrome.Brain communications · 2021Article
- Predicting 12-month functional outcome in Guillain-Barré syndrome by combining acute-phase clinical data and traditional Chinese medicine syndrome features: a retrospective machine learning study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this review was to analyse the pathophysiology of axonal degeneration in Guillain-Barré syndrome (GBS) with emphasis on early stages (≤ 10 days after onset). An overview of experimental autoimmune neuritis (EAN) models is provided. Originally GBS and acute inflammatory demyelinating polyneuropathy were equated, presence of axonal degeneration being attributed to a "bystander" effect. Afterwards, primary axonal GBS forms were reported, designated as acute motor axonal neuropathy/acute motor-sensory axonal neuropathy. Revision of the first pathological description of axonal GBS indicates the coexistence of active axonal degeneration and demyelination in spinal roots, and pure Wallerian-like degeneration in peripheral nerve trunks. Nerve conduction studies are essential for syndrome subtyping, though their sensitivity is scanty in early GBS. Serum markers of axonal degeneration include increased levels of neurofilament light chain and presence of anti-ganglioside reactivity. According to nerve ultrasonographic features and autopsy studies, ventral rami of spinal nerves are a hotspot in early GBS. In P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.